Position
Parallel Advisors, LLC in Regeneron Pharmaceuticals, Inc.
Back to the book · All holders of REGN
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $547$772.60 → $773.15
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 995 | $768.7K | — | — | — | 0.0% |
| Q1 2026 | 1.11K | $855.9K | $773.15 | $547 | $86.6K | 0.0% |